Propanc Biopharma (QB) Stock Price - PPCB

0.0112
0.0023 (25.84%)
0.0112
Best deals to access real time data!
Small Cap Basic
Monthly Subscription
for only
$33.03
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Propanc Biopharma Inc (QB) PPCB OTCMarkets Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.0023 25.84% 0.0112 0.009 0.0124 0.00915 0.0089 16:27:36
Bid Price Ask Price Spread Spread % News
0.011 0.012 0.001 8.33% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
232 5,994,207 $ 0.011164 $ 66,919 3,150,759 0.0066 - 2.57
Last Trade Time Type Quantity Stock Price Currency
15:59:31 1,000 $ 0.0112 USD

Propanc Biopharma (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 624.95k 55.80M 1.27M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
53.91k $ - 0.00% - -

more financials information »

Propanc Biopharma (QB) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PPCB Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.00980.01240.00740.00861456,861,5050.001414.29%
1 Month0.0140.0150.00740.01042175,956,612-0.0028-20.0%
3 Months0.0450.0710.00740.01539953,271,860-0.0338-75.11%
6 Months0.394951.750.00740.02942891,700,421-0.38375-97.16%
1 Year0.0082.570.00660.02985041,068,3590.003240.0%
3 Years1.212.570.00390.05655692,280,245-1.20-99.07%
5 Years0.0742.700.00390.04086943,833,327-0.0628-84.86%

Propanc Biopharma (QB) Description

Propanc Biopharma is a biopharmaceutical company that focuses on the development of new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. The Company's lead product candidate, PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically.


Your Recent History
USOTC
PPCB
Propanc Bi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.